Archive for March 5th, 2009|Daily archive page

Cord Blood Banking – Pros and Cons of this Medical Procedure

In ALL ARTICLES, STEM CELLS IN THE NEWS on March 5, 2009 at 11:35 am


An alternative to banking cord stem cells if you missed the opportunity or their storage is too expensive is milk tooth storage…
“StemSave harvests stem cells from teeth already pulled by your dentist, which are delivered to its lab in a patented transportation kit that keeps cells alive by chilling them. All stem cells aren’t created equal, but StemSave CEO Art Greco claims that cells from teeth are particularly versatile — and the younger the tooth, the better. The service costs $590 to join, and $100 per year after that.”


What is cord-blood banking?

Cord blood banking refers to the collection and storage of the umbilical cord blood of your child. This blood, from the placenta and umbilical cord, is rich in hematopoietic stem cells. Stem cells from this cord blood play an important role in the treatment of certain serious blood and immune system related genetic diseases such as cancers that are treated with bone marrow transplants.


* Cord blood stem cells have a higher success rate than stem cells from the bone marrow.

* They are valuable in treating conditions such as leukemia or lymphoma, aplastic anemia, severe sickle cell anemia, severe combined immune deficiency, and other diseases that require bone marrow transplants.

* They may prove useful for a family that has a medical history of diseases that are usually treated using bone marrow transplants.


* The odds that the baby’s cord blood will ever be used to treat a family member are very low; odds that it will ever be used to treat the same child are even lower.

* It is expensive. Storing a sample of cord blood may cost approximately $1, 500, along with an annual maintenance of $ 150.

* It has limited use. Cord blood stem cells are mostly used in the treatment of children and young adults. The quantity of stem cells provided by cord blood is not enough for transplant into adults.

* It is not yet certain whether stem cells from close relatives actually offer a higher rate of success than those from strangers.

* The process of collecting the blood holds some risk, though very low, to the baby.

via Cord Blood Banking – Pros and Cons of this Medical Procedure.

Video: Using dog fat cells to treat arthritis | NBC13.com

In ALL ARTICLES, VICTORIES & SUCCESS STORIES on March 5, 2009 at 11:29 am

saddogPublished: March 5, 2009

Imagine watching your dog become crippled, with no relief from drugs or surgery.

That’s what happened to one California pet owner.

Fortunately she found a life-saving treatment using the dog’s own fat.

It’s hard to believe seeing it now, but a couple of months ago Abby, a 6-year old shelty, could barely walk.

“we were talking about euthanizing her because she was in so much pain,“ said owner Vicky Rusconi.

Rusconi tried countless procedures to help her dog’s debilitating arthritis, but nothing worked.

When a vet at the animal clinic where she works recommended injecting stem cells using Abby’s own fat, she figured she had nothing to lose.

“I was skeptical to be honest, but I was willing to try anything,“ Rusconi said. “I think when you get to the point where it’s either euthanize your dog or try a new procedure, you’re willing to try it.“

Since the first round worked so well, Abby is now undergoing a second round of stem cell injections using her own fat.

via Video: Using dog fat cells to treat arthritis | NBC13.com.

CATCH UP! – UK’s Stem Cell Sciences acquired by US company

In ALL ARTICLES, STEM CELLS IN THE NEWS on March 5, 2009 at 11:27 am

shhWith the ever so quiet announcement that the NIH is getting into adult stem cell research, the bugle has been (oh so quietly) blown for the United States.  It is no longer a question of whether the US is 5-10 years behind in adult stem cell research, it is only a question of what can be done?

StemCells, Inc is one of the first to see this and their purchase of the UK stem cell company may allow them to pursue stem cell R&D outside the US is an effort to keep pace with the rest of the world and try to CATCH UP! – dg

Thursday , March 05, 2009

US company StemCells Inc is to expand its capabilities in the field with the purchase of UK based Stem Cell Sciences for $4.8 million.

Established in 1994, Stem Cell Sciences is based in Cambridge in the UK and specialises in developing stem cells to be used in drug discovery and regenerative medicine research.

The company has a second research base in Monash near Melbourne, Australia, and this will also be included in the sale to the US group.

California-based StemCells Inc is developing stem cell products for therapeutic use in humans. It says its combination with Stem Cell Sciences will provide a major boost to its commercial base.

“The industrial logic of this acquisition is compelling,” said Martin McGlynn, president and chief executive of StemCells. “StemCells has established itself as a world leader in tissue-derived stem and progenitor cells for therapeutic uses, while Stem Cell Sciences has focused on non-therapeutic applications for embryonic and tissue derived stem cells, such as cell-based assays for drug discovery and screening.”

McGlynn said the combination of three distinct stem cell platforms, adult, embryonic and iPS cells, for both therapeutic and drug discovery applications would allow the company to diversify and pursue near-term opportunities while continuing to develop its therapeutic products.

via Pharmafocus.com.

New Study Using Combination of Bioengineered Skin and Stem Cells Shows Promise in Treatment of Non-Healing Wounds | LifeSciencesWorld

In ALL ARTICLES, STEM CELLS IN THE NEWS on March 5, 2009 at 12:21 am

skinNew Study Using Combination of Bioengineered Skin and Stem Cells Shows Promise in Treatment of Non-Healing Wounds

posted on 05/03/2009

Scleroderma is an autoimmune disease that leads to thickening and severe scarring of skin as well as thickening and failure of internal organs, including the lungs, heart, kidneys and intestines. The disease — which the Scleroderma Foundation estimates affects approximately 300,000 Americans — can be fatal and there is no cure. A major and incapacitating complication of scleroderma is the development of ulcers on the patients’ fingers and toes that are very painful and difficult to heal. Now, researchers are studying the viability of administering stem cells topically to ulcerated fingers using bioengineered skin to help heal these wounds.

via New Study Using Combination of Bioengineered Skin and Stem Cells Shows Promise in Treatment of Non-Healing Wounds | LifeSciencesWorld.

%d bloggers like this: